1. Table of Contents
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Agoraphobia Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Agoraphobia Clinical Trials by Region
2.2.2 Average Enrollment of Agoraphobia Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Agoraphobia Treatment, 2019

3. Region wise Agoraphobia Clinical Trials
3.1 Asia Pacific Agoraphobia Clinical Trials by Country
3.2 Europe Agoraphobia Clinical Trials by Country
3.3 North America Agoraphobia Clinical Trials by Country
3.4 Middle East and Africa Agoraphobia Clinical Trials by Country
3.5 South and Central America Agoraphobia Clinical Trials by Country

4. Agoraphobia Clinical Trial Trends
4.1 Start Year wise Agoraphobia Clinical Trials
4.2 Phase wise Agoraphobia Clinical Trials
4.3 Trial Status wise Agoraphobia Clinical Trials
4.4 Trial Type wise Agoraphobia Clinical Trials

5. Agoraphobia Average Enrollment Trends
5.1 Average Enrollment in Agoraphobia Trials by Year
5.2 Average Enrollment in Agoraphobia Trials by Phase
5.3 Average Enrollment in Agoraphobia Trials by Status
5.4 Average Enrollment in Agoraphobia Trials by Type of Trial

6. Companies Participating in Agoraphobia Clinical Trials
6.1 Agoraphobia Trials by Sponsor Type
6.2 Agoraphobia Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Agoraphobia Trials- Phase 1
7.2 Agoraphobia Trials- Phase 2
7.3 Agoraphobia Trials- Phase 3
7.4 Agoraphobia Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Agoraphobia Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Agoraphobia Clinical Trials and Enrolment
Figure 5: Europe – Country wise Agoraphobia Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Agoraphobia Clinical Trials and Enrolment
Figure 7: North America – Country wise Agoraphobia Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Agoraphobia Clinical Trials and Enrolment
Figure 9: Agoraphobia Clinical Trials by Phase
Figure 10: Agoraphobia Clinical Trials by Trial Status
Figure 11: Agoraphobia Clinical Trials by Type
Figure 12: Agoraphobia Clinical Trials by Sponsor Type
Figure 13: Agoraphobia Clinical Trials by Leading Sponsors
Figure 14: Agoraphobia Average Enrollment by Phase
Figure 15: Agoraphobia Average Enrollment by Trial Status
Figure 16: Agoraphobia Average Enrollment by Type
Figure 17: Agoraphobia- Average Enrolment by Type of Sponsors
Figure 18: Agoraphobia- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List of Tables
Table 1: Agoraphobia Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Agoraphobia Clinical Trials and Enrolment
Table 5: Europe – Country wise Agoraphobia Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Agoraphobia Clinical Trials and Enrolment
Table 7: North America – Country wise Agoraphobia Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Agoraphobia Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Agoraphobia Average Enrollment by Phase
Table 15: Agoraphobia Average Enrollment by Trial Status
Table 16: Agoraphobia Average Enrollment by Type
Table 17: Agoraphobia- Average Enrolment by Type of Sponsors
Table 18: Agoraphobia- Enrolment by Leading Sponsors

Companies mentioned
Alfred E. Tiefenbacher GmbH & Co KG, Bluefish Pharmaceuticals AB, Dexcel PT Holdings Ltd, Eli Lilly and Co, Mylan NV, Pfizer Inc, Syneos Health Inc, The Lundbeck Foundation, Torrent Pharmaceuticals Ltd, Wockhardt Ltd